Federal Register / Vol. 61, No. 81 / Thursday, April 25, 1996 / Notices 18397

Board of Governors of the Federal Reserve

System, April 19, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96-10147 Filed 4-24-96; 8:45 am]

BILLING CODE 6210-01-F

Notice of Proposals to Engage in

Permissible Nonbanking Activities or

to Acquire Companies That are

Engaged in Permissible Nonbanking

Activities

The companies listed in this notice

have given notice under section 4 of the

Bank Holding Company Act (12 U.S.C.

1843) (BHC Act) and Regulation

Y, (12 CFR part 225) to engage de novo,

or to acquire or control voting securities

or assets of a company that engages

either directly or through a subsidiary or

other company, in a nonbanking activity

that is listed in § 225.25 of Regulation

Y (12 CFR 225.25) or that the Board has

determined by Order to be closely

related to banking and permissible for

bank holding companies. Unless

otherwise noted, these activities will be

conducted throughout the United States.

Each notice is available for inspection

at the Federal Reserve Bank indicated.

Once the notice has been accepted for

processing, it will also be available for

inspection at the offices of the Board of

Governors. Interested persons may

express their views in writing on the

question whether the proposal complies

with the standards of section 4 of the

BHC Act, including whether

consummation of the proposal can

‘‘reasonably be expected to produce

benefits to the public, such as greater

convenience, increased competition, or

gains in efficiency, that outweigh

possible adverse effects, such as undue

concentration of resources, decreased or

unfair competition, conflicts of

interests, or unsound banking practices’’

(12 U.S.C. 1843). Any request for a

hearing on this question must be

accompanied by a statement of the

reasons a written presentation would

not suffice in lieu of a hearing,

identifying specifically any questions of

fact that are in dispute, summarizing the

evidence that would be presented at a

hearing, and indicating how the party

commenting would be aggrieved by

approval of the proposal.

Unless otherwise noted, comments

regarding the applications must be

received at the Reserve Bank indicated

or the offices of the Board of Governors

not later than May 8, 1996.

A. Federal Reserve Bank of New

York (Christopher J. McCurdy, Senior

Vice President) 33 Liberty Street, New

York, New York 10045:

1. Waterhouse Investor Services, Inc.,

New York, New York; to engage de novo

through its subsidiary, Waterhouse

Securities Inc., New York, New York,

and thereby engage in the purchase and

sale of securities on the order of

customers as a ‘‘riskless principal’’,

pursuant to Bankers Trust New York

Corp., 75 Fed. Res. Bull. 829 (1989).

B. Federal Reserve Bank of

Richmond (Lloyd W. Bostian, Jr., Senior

Vice President) 701 East Byrd Street,

Richmond, Virginia 23261:

1. Allied Irish Banks, p.l.c., Dublin,

Ireland; and First Maryland Bancorp,

Baltimore, Maryland; to acquire

Washington Federal Savings Bank,

Herndon, Virginia, and thereby

indirectly acquire 1st Washington

Bancorp, Inc., Herndon, Virginia, and

thereby engage in operating a savings

bank, pursuant to § 225.25(b)(9) of the

Board’s Regulation Y, in mortgage

origination and servicing, pursuant to §

225.25(b)(1) of the Board’s Regulation Y;

and in the sale of property and casualty

insurance and group life and health

insurance, pursuant to § 225.25(b)(8) of

the Board’s Regulation Y.

2. American Bankshares, Inc., Welch,

West Virginia; to engage de novo

through its subsidiary, Ameriloan,

Englewood, Colorado, in consumer

financing, pursuant to § 225.25(b)(1)(i)

of the Board’s Regulation Y.

Board of Governors of the Federal Reserve

System, April 19, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96-10148 Filed 4-24-96; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Meeting of the

Sickle Cell Disease Advisory

Committee

Pursuant to Public Law 92–463,

notice is hereby given of the meeting of

the Sickle Cell Disease Advisory

Committee, National Heart, Lung, and

Blood Institute, June 7, 1996. The

meeting will be held at the National

Institutes of Health, Two Rockledge

Center, Conference Room 9A1–A2, 6701

Rockledge Drive, Bethesda, Maryland

20892.

The entire meeting will be open to the

public from 9:00 a.m. to adjournment, to

discuss recommendations on the

implementation and evaluation of the

Sickle Cell Disease Program. Attendance

by the public will be limited to space

available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact the Executive Secretary in

advance of the meeting.

Dr. Clarice D. Reid, Executive

Secretary, Sickle Cell Disease Advisory

Committee, Division of Blood Diseases

and Resources, NHLBI, Two Rockledge

Center, Suite 10160, 6701 Rockledge

Drive, Bethesda, Maryland 20892, (301)

435–0080, will furnish substantive

program information, a summary of the

meeting, and a roster of the committee

members.

(Catalog of Federal Domestic Assistance

Program No. 93.839, Blood Diseases and

Resources Research, National Institutes of

Health)

Dated: April 22, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–10197 Filed 4–24–96; 8:45 am]

BILLING CODE 4140–01–M

Notice of Meeting of the National

Advisory Council for Human Genome

Research

Pursuant to Public Law 92–463,

notice is hereby given of the meeting of

the National Advisory Council for

Human Genome Research, National

Center for Human Genome Research,

May 20–21, 1996, Holiday Inn,

Washington/Chevy Chase, Palladian

East/Center, 5520 Wisconsin Avenue,

Chevy Chase, Maryland.

This meeting will be open to the

public on Monday, May 20, from 8:30

a.m. to 11:30 a.m. to discuss

administrative details or other issues

relating to committee activities.

Attendance by the public will be limited

to space available.

In accordance with the provisions set

forth in sections 552b(c)(4) and

552b(c)(6), Title 5, U.S.C. and section

10(d) of Public Law 92–463, the meeting

will be closed to the public on May 20

at 11:30 a.m. to recess and on May 21

from 8:30 a.m. to adjournment, for the

review, discussion and evaluation of

individual grant applications. The

applications and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material, and personal information

concerning individuals associated with

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Dr. Elke Jordan, Deputy Director,

National Center for Human Genome

Research, National Institutes of Health,